{"id":56792,"date":"2026-02-10T23:18:40","date_gmt":"2026-02-10T15:18:40","guid":{"rendered":"https:\/\/flcube.com\/?p=56792"},"modified":"2026-02-10T23:18:41","modified_gmt":"2026-02-10T15:18:41","slug":"henlius-biotech-secures-global-rights-to-u-mabs-il-1rap-antibody-in-licensing-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56792","title":{"rendered":"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal"},"content":{"rendered":"\n<p><strong>Shanghai Henlius Biotech, Inc.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a><\/strong>) announced a <strong>licensing agreement<\/strong> with <strong>U-mab Biopharma<\/strong>, acquiring <strong>exclusive global rights<\/strong> to a <strong>potential best-in-class (BIC) monoclonal antibody<\/strong> targeting <strong>interleukin-1 receptor accessory protein (IL-1RAP)<\/strong>. The deal expands Henlius&#8217;s <strong>inflammation and immunology portfolio<\/strong> into a <strong>novel pathway with no approved competitors worldwide<\/strong>, leveraging promising preclinical efficacy and long-acting pharmacokinetic properties.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>U-mab Biopharma (China-based)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Shanghai Henlius Biotech, Inc. (HKG: 2696)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>IL-1RAP-targeting monoclonal antibody<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Potential best-in-class (BIC)<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td>Exclusive global development and commercialization<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Interleukin-1 receptor accessory protein (IL-1RAP)<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td><strong>No approved therapies globally targeting IL-1RAP pathway<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-data-package\">Preclinical Data Package<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Finding<\/th><th>Strategic Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Efficacy<\/strong><\/td><td>Excellent activity in <strong>various animal models<\/strong><\/td><td>Broad therapeutic potential across multiple indications<\/td><\/tr><tr><td><strong>Natural Disease Models<\/strong><\/td><td>Significant therapeutic effects in <strong>spontaneous animal diseases<\/strong><\/td><td>Translational relevance to human pathology<\/td><\/tr><tr><td><strong>Pharmacokinetics<\/strong><\/td><td><strong>Long half-life<\/strong> supported by animal PK data<\/td><td>Enables <strong>long-interval dosing<\/strong> (potentially monthly or quarterly)<\/td><\/tr><tr><td><strong>Druggability<\/strong><\/td><td>Favorable developability profile<\/td><td>Reduced CMC risks and manufacturing costs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-biology-amp-therapeutic-rationale\">Target Biology &amp; Therapeutic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL-1RAP Function:<\/strong> <strong>Interleukin-1 receptor accessory protein<\/strong> is a <strong>co-receptor for IL-1, IL-33, and IL-36 signaling<\/strong>\u2014central to <strong>innate immunity, inflammation, and fibrosis<\/strong><\/li>\n\n\n\n<li><strong>Pathway Validation:<\/strong> IL-1 pathway blockade (anakinra, canakinumab) validated in <strong>rheumatoid arthritis, periodic fever syndromes, and cardiovascular inflammation<\/strong>; IL-1RAP targeting offers <strong>broader cytokine inhibition<\/strong> with single agent<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> IL-1RAP antibody potentially addresses <strong>IL-1\u03b1, IL-1\u03b2, IL-33, and IL-36 simultaneously<\/strong> vs. selective IL-1\u03b2 or IL-1R1 approaches<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> No approved IL-1RAP inhibitors; opportunity in <strong>autoinflammatory diseases, fibrotic conditions, and potentially oncology<\/strong> (IL-33\/ST2 tumor microenvironment)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-pipeline-context\">Strategic Positioning &amp; Pipeline Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Henlius Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Rights<\/strong><\/td><td>Full control of development strategy and ex-China partnership economics<\/td><\/tr><tr><td><strong>First-in-Class Potential<\/strong><\/td><td>No competitors in clinic; patent landscape freedom<\/td><\/tr><tr><td><strong>Long-Acting Format<\/strong><\/td><td>Competitive advantage in chronic disease adherence vs. existing IL-1 biologics requiring frequent dosing<\/td><\/tr><tr><td><strong>Portfolio Diversification<\/strong><\/td><td>Expands beyond oncology (biosimilars, novel mAbs) into <strong>high-value immunology<\/strong><\/td><\/tr><tr><td><strong>U-mab Validation<\/strong><\/td><td>Chinese biotech ecosystem collaboration; access to novel targets without early-stage discovery costs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>Preclinical candidate optimization and IND-enabling studies<\/td><td>2026<\/td><\/tr><tr><td><strong>Near-term<\/strong><\/td><td>IND submission to NMPA (China) and FDA (US)<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Clinical<\/strong><\/td><td>Phase I healthy volunteer and patient studies<\/td><td>2027<\/td><\/tr><tr><td><strong>Expansion<\/strong><\/td><td>Indication selection (autoinflammatory, fibrosis, or immuno-oncology)<\/td><td>Data-driven<\/td><\/tr><tr><td><strong>Global<\/strong><\/td><td>Ex-China partnership or self-commercialization decision<\/td><td>2028+<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IL-1RAP antibody clinical development timelines, first-in-class market positioning, and Henlius Biotech&#8217;s immunology portfolio expansion. Actual results may differ due to translation risks from animal to human efficacy, competitive entry into IL-1RAP space, and immunology drug development timelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[270,862,4600],"class_list":["post-56792","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-henlius-biotech","tag-hkg-2696","tag-u-mab-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive global rights to a potential best-in-class (BIC) monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). The deal expands Henlius&#039;s inflammation and immunology portfolio into a novel pathway with no approved competitors worldwide, leveraging promising preclinical efficacy and long-acting pharmacokinetic properties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56792\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive global rights to a potential best-in-class (BIC) monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). The deal expands Henlius&#039;s inflammation and immunology portfolio into a novel pathway with no approved competitors worldwide, leveraging promising preclinical efficacy and long-acting pharmacokinetic properties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56792\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T15:18:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T15:18:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56792#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56792\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal\",\"datePublished\":\"2026-02-10T15:18:40+00:00\",\"dateModified\":\"2026-02-10T15:18:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56792\"},\"wordCount\":438,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Henlius Biotech\",\"HKG: 2696\",\"U-mab Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56792#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56792\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56792\",\"name\":\"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-10T15:18:40+00:00\",\"dateModified\":\"2026-02-10T15:18:41+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive global rights to a potential best-in-class (BIC) monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). The deal expands Henlius's inflammation and immunology portfolio into a novel pathway with no approved competitors worldwide, leveraging promising preclinical efficacy and long-acting pharmacokinetic properties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56792#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56792\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56792#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive global rights to a potential best-in-class (BIC) monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). The deal expands Henlius's inflammation and immunology portfolio into a novel pathway with no approved competitors worldwide, leveraging promising preclinical efficacy and long-acting pharmacokinetic properties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56792","og_locale":"en_US","og_type":"article","og_title":"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal","og_description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive global rights to a potential best-in-class (BIC) monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). The deal expands Henlius's inflammation and immunology portfolio into a novel pathway with no approved competitors worldwide, leveraging promising preclinical efficacy and long-acting pharmacokinetic properties.","og_url":"https:\/\/flcube.com\/?p=56792","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-10T15:18:40+00:00","article_modified_time":"2026-02-10T15:18:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56792#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56792"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal","datePublished":"2026-02-10T15:18:40+00:00","dateModified":"2026-02-10T15:18:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56792"},"wordCount":438,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Henlius Biotech","HKG: 2696","U-mab Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56792#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56792","url":"https:\/\/flcube.com\/?p=56792","name":"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-10T15:18:40+00:00","dateModified":"2026-02-10T15:18:41+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a licensing agreement with U-mab Biopharma, acquiring exclusive global rights to a potential best-in-class (BIC) monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). The deal expands Henlius's inflammation and immunology portfolio into a novel pathway with no approved competitors worldwide, leveraging promising preclinical efficacy and long-acting pharmacokinetic properties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56792#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56792"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56792#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Biotech Secures Global Rights to U-mab\u2019s IL-1RAP Antibody in Licensing Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56792"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56792\/revisions"}],"predecessor-version":[{"id":56794,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56792\/revisions\/56794"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}